Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1244707 | 0.87 | CALM1 (0.46) | MAOAMAOBIDH1ALDH1A1 | |
| SCHEMBL27971613 | 0.81 | TSHR (0.50) | DAOMAOAMAOB | |
| SCHEMBL23784751 | 0.77 | ALDH1A1 (0.32) | GPR84ALDH1A1 | |
| SCHEMBL28473089 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL934450 | 0.72 | — | — | |
| SCHEMBL31349737 | 0.72 | AKR1B1 (0.39) | TDP1CA2ALDH1A1HPGDALOX15 | |
| SCHEMBL23122001 | 0.72 | ALDH1A1 (0.55) | DAOPPARGTDP1FAAHMAOA | |
| SCHEMBL17398385 | 0.71 | PNMT (0.41) | DAOALDH1A1 | |
| SCHEMBL250034 | 0.71 | CTRC (0.45) | TDP1ALDH1A1 | |
| SCHEMBL7136305 | 0.70 | ALDH1A1 (0.58) | DAOTDP1MAOAMAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884124-B2 | such as 2-Fluoro-4H-furo[3,2-b]pyrrole-5-carboxylate acid, used for the treatment of neuropathic pain, Alzheimer's disease, schizophrenia, ataxia and convulsions | SEPRACOR INC. (US) | 2011-02-08 | — | — | US | disclosed |
| CN-101820760-A | Condensed hetero ring | SEPRACOR INC | 2010-09-01 | — | — | CN | disclosed |
| EP-2173170-A2 | FUSED HETEROCYCLES | Sepracor Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20100029741-A1 | FUSED HETEROCYCLES | SEPRACOR INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100022612-A1 | FUSED HETEROCYCLES | SEPRACOR INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-7579370-B2 | Fused heterocycles | SEPRACOR INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-2057162-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | Sepracor Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009020814-A2 | FUSED HETEROCYCLES | SEPRACOR INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | SEPRACOR INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005456-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005456-A2 | FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004328-A1 | FUSED HETEROCYCLES | SEPRACOR INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022612-A1 | FUSED HETEROCYCLES | AHR, HAX1, HRH3 | DAO 2452/4885PPARG 2903/4885TDP1 4620/4885 |
| US-20080058395-A1 | Fused heterocyclic inhibitors of D-amino acid oxidase | DAO, DDO, AOX1 | DAO 1/4885PPARG 4448/4885TDP1 707/4885 |
| US-20100029741-A1 | FUSED HETEROCYCLES | CHRNA4, CHRNB4, CHRNA3 | DAO 1545/4885PPARG 1608/4885TDP1 2626/4885 |
| US-20080004328-A1 | FUSED HETEROCYCLES | HRH3, HRH4, AHR | DAO 2936/4885PPARG 3094/4885TDP1 4468/4885 |
| US-20080004327-A1 | FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE | DAO, DDO, AOX1 | DAO 1/4885PPARG 4537/4885TDP1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.